Background and objective: The clinical outcome and angiographic outcome data of Woven EndoBridge (WEB) device for the treatment of ruptured intracranial aneurysms (IAs) are limited. We conducted a meta-analysis of the latest literature on the WEB device in the treatment of ruptured IAs. Methods: A comprehensive literature search of 4 databases (PubMed, Web of Science, Cochrane library, and Embase) was conducted for studies published from January 1, 2010 to December 31, 2020. Two reviewers independently extracted variables (aneurysm and patient characteristics) using a prespecified data-collection sheet. Outcomes studied included initial and latest follow-up angiographic outcomes, technical success rate, perioperative mortality, retreated rate, perioperative re-bleeding, complication, intraoperative rupture, favorable neurologic outcome at discharge. We used random-effects model to pool the data. Results: We finally presented the results of 7 articles including 276 patients with 283 aneurysms. Initial complete and adequate occlusion rate were 38% (95% CI, 25%–50%) and 98% (95% CI, 95%–100%), respectively. Latest follow-up complete and adequate occlusion rate were 61% (95% CI, 46%–75%) and 91% (95% CI, 84%–98%), respectively.Technical success rate was 99% (95% CI, 98%–100%). Perioperative mortality rates and perioperative re-bleeding rate were 9% (95% CI, 3%–15%) and 1% (95% CI, 0%–2%), respectively. Retreated rate was 6% (95% CI, 3%–10%). Overall and WEB treatment-related thromboembolic complication was 10% (95% CI, 6%–13%) and 7% (95% CI, 2%–12%), respectively. Intraoperative rupture rate was 3% (95% CI, 0%–6%). Conclusion: Endovascular treatment of ruptured IAs with the WEB device has a good safety profile and an acceptable aneurysm occlusion rate.

Background: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but its efficacy varies due to patient heterogeneity. Combining TACE with systemic therapies, such as targeted agents or immune checkpoint inhibitors, has shown promise in improving outcomes, though controversies regarding survival benefits and safety persist. This study investigates whether synchronized systemic therapy enhances the therapeutic efficacy of TACE in intermediate and advanced-stage HCC. Methods: This single-center, retrospective study included 142 patients with intermediate and advanced-stage HCC (BCLC B or C) who received TACE as initial treatment between February 2019 and August 2022 at Hunan Provincial People’s Hospital. Patients were divided into two groups: combination therapy (TACE plus systemic therapy, n=41) and TACE monotherapy (n=101). Progression-free survival (PFS), overall survival (OS), treatment response (per mRECIST criteria), and adverse events (AEs) were compared. Cox regression and Kaplan-Meier analyses were used to assess survival outcomes. Results: No significant differences were observed in baseline characteristics, except for a higher proportion of Child-Pugh A patients in the combination group (90.2% vs. 67.3%, P= 0.005). Median PFS was similar between the combination and monotherapy groups (5.5 vs. 6.0 months, P= 0.832), with no significant differences in BCLC-B (18.3 vs. 17.4 months, P= 0.516) or BCLC-C (4.1 vs. 3.7 months, P= 0.255) subgroups. However, the combination group showed a trend toward improved OS (24.8 vs. 16.7 months, P= 0.282), with a significant benefit in BCLC-C patients (17.9 vs. 11.0 months, P= 0.048). Grade 3 or 4 AEs were comparable between groups (7.2% vs. 14.9%, P= 0.187). Conclusion: Combining systemic therapy with TACE does not improve PFS but may enhance OS in BCLC-C patients. The safety profile is comparable, particularly in patients with preserved liver function. These findings highlight the importance of patient selection and warrant further prospective studies to optimize treatment strategies.

Background: Previous studies have revealed obesity, nutrition, lifestyle, genetic and epigenetic factors may be risk factors for the occurrence and development of non-alcoholic fatty liver disease (NAFLD). However, the effect of total polyunsaturated fatty acid (PUFA) consumption on the risk of NAFLD is uncertain. Therefore, this study aimed to determine whether the total PUFA intake is independently associated with the risk of NAFLD and explore the threshold of PUFA intake better illustrate the correlation between them in Chinese Han adults.Methods: The present study was a retrospective case–control study. A total of 534 NAFLD patients and 534 controls matched by gender and age in the same center were included in this study. Using a semi-quantitative food frequency questionnaire in a health examination center in China to collect information about dietary intake and calculate nutrient consumption. A multivariate logistic regression model was used to estimate the association between total PUFA daily intake and its quartile and the incidence of NAFLD.Results: Multivariate analyses suggested a significant association between total PUFA intake and the occurrence of NAFLD. A non-linear relationship between total PUFA consumption and NAFLD risk was detected after adjusting for potential confounding factors. There was a significant connection between PUFA and the risk of NAFLD (OR: 1.32, 95% CI: 1.23–1.41,P < 0.0001) when PUFA intake is between 18.8 and 29.3 g/day.Conclusions: The relationship between total PUFA intake and NAFLD is non-linear. Total PUFA was positively related to the risk of NAFLD when PUFA intake is between 18.8 and 29.3 g/day among Chinese Han adults.

Background: Although the research on the risk factors of anterior communicating artery (AComA) aneurysm has made great progress, the independent effect of each risk factor on the rupture of AComA aneurysm is controversial among different studies. We will perform a protocol for systematic review and meta-analysis to investigate risk factors for AComA aneurysm rupture and quantify their independent effects. Methods: A systematic search according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols guidelines in PubMed, Embase, and the Cochrane Library databases was conducted from inception to August 31, 2021 for published studies concerning risk factors for AComA aneurysm rupture. In the absence of statistical heterogeneity (ie, P > .10 and I ² < 50%), we will use a fixed-effects model to pool the results across sufficient studies. Otherwise, we will present the results employing the random-effects model. Quality assessment of the included studies will be evaluated using the Newcastle–Ottawa Scale. Statistical analyses will be performed using Stata16 (Stata Corporation, College Station, TX, USA) software. Results: The findings of this study will be submitted to peer-reviewed journals for publication. Conclusion: This systematic review will provide evidence to determine the risk factors that affect the rupture of the AComA aneurysm and quantify their independent effects. Ethics and dissemination: Since the proposed study uses pre-published data, ethical approval is not required. Review registration number: CRD42021284262. (https://www.crd.york.ac.uk/PROSPERO/).

This study aims to introduce the diagnosis and treatment processes of traumatic splenic bleeding and explain its emergency, medical, interventional, and surgical treatments. Furthermore, this study aims to summarize the indications and contraindications of splenic artery embolization, interventional procedures, and precautions of complications.